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Background: Psoriasis is a chronic, inflammatory disease affecting 2-3% of the worldwide 
population, and it may worsen with HIV or be detected as HIV cutaneous manifestation. 
HIV-related psoriasis shows a severe and prolonged clinical course with more frequent 
exacerbations. The management of this condition is challenging because im-
munomodulating and immunosuppressant agents may have variable and partial efficacy, 
and therefore, antiretroviral treatment represents a potential adjunctive therapeutic option. 
Results: In the case we report, the HIV test was shown to be crucial for driving the 
therapeutic approach. Indeed, antiretroviral agents have been proven to be effective in the 
treatment of HIV+ psoriasis as first-line therapy. Conclusion: The HIV test should be 
considered in high-risk patients affected by severe psoriasis and resistant to conventional 
and biological treatments. 
 
Introduction 
Psoriasis is a chronic, inflammatory disease affecting 2-3% of the worldwide population [1]. 
The most common clinical phenotype, namely plaque-type psoriasis, is characterized by 
symmetrical, erythematosus, scaly plaques localized on the extensor surfaces of the skin, 
scalp, and lower back, although any site can be affected. Psoriasis may represent a 
cutaneous manifestation of human immunodeficiency virus (HIV) infection, and can 
potentially provide clinical evidence regarding the progression of the infection [2]. 
Hence, a worsening of psoriasis in high-risk patients (e.g. story of drug abuse, hepatitis C 
virus, HCV, infection) or in patients with a multidrug resistance might be determined by a 
latent infection which laboratory tests can easily detect, with the exception of the HIV test 
which legally needs a written consent signed by patients who, in some cases, could be 
reluctant to perform it. Though HIV testing is not mandatory in the screening for biological 
therapies, it could prove very useful in the selection of the optimal therapeutic option for 
the treatment of a challenging condition such as HIV-related psoriasis. 
 We present the case of severe psoriasis associated with an undiagnosed HIV infection 
that was found to be resistant to multiple antipsoriatic therapies. Diagnosis and treatment 
of HIV led to an improvement of the skin condition. 
Moreover, we reviewed the literature, focusing our attention on the wide therapeutic 
armamentarium available in the treatment of HIV-related psoriasis. 
 
Case report 
A 50-year-old Caucasian man, affected by moderate-to-severe plaque-type psoriasis since 
the age of 40 years, was referred to our Department with a severe erythrodermic flare. The 
patient's clinical notes mentioned a chronic, asymptomatic HCV infection since the age of 
30. The patient was unresponsive to conventional systemic antipsoriatic treatments 
(cyclosporine 3 mg/kg daily and acitretin 25 mg daily) and systemic steroids 
(methylprednisolone 0.5 mg/kg daily), claiming that erythrodermic flares characterized all 
episodes of psoriasis exacerbations. Screening for biologicals, according to European 
Guidelines [1], was performed. Serum transaminases were within normal ranges, the HCV 
replication rate was low, and ul-trasound demonstrated that liver dimension and 
parenchyma structure were conserved. According to blood and imaging results, the patient 
was considered eligible for biologicals. Of note, the patient refused to sign the informed 
consent for an HIV test recommended (but not mandatory)[1] prior to a biological therapy. 
Then infliximab, a chimeric anti-tumor necrosis factor (TNF)-α monoclonal antibody, 5 
mg/kg intravenously, was initiated. A significant improvement was observed as soon as 
week 2, but a loss of efficacy leading to drug discontinuation was observed at week 30 
and, after a 3-month washout period, the patient was switched to adalimumab, a human 
anti-TNF-α monoclonal antibody, 40 mg every other week. Similarly to infliximab, 
adalimumab initially controlled psoriasis but was discontinued because of inefficacy after 
18 months of continuous treatment. Adverse events were not referred during infliximab or 
adalimumab treatment; in contrast, erythrodermic flares and loss of efficacy to both anti-
TNF-α agents were observed. A screening evaluation for biological eligibility was again 
performed and, remarkably, again the patient refused signing the HIV test consent form. 
Etanercept 50 mg twice weekly was subcutaneously administered and suddenly, after the 
third injection, the patient was referred to our outpatient clinic with erythroderma (PASI 48), 
fever (39.2°C), and a nonproductive cough. The patient's clinical conditions were severe, 
deserving hospitalization. Blood tests, including urine culture and hemoculture for 
mycetes, aerobic and anaerobic bacteria, were performed. Cell blood count showed 
increased neutrophils with a reduction of CD3+/CD45+ T lymphocytes (520 cells/ml; 
normal range: 690-2,540 cells/ml). Several pathogens, including HCV, hepatitis B and A 
virus, tuberculosis, Treponema pallidum, Toxoplasma, herpes simplex virus 1-2, varicella-
zoster virus, cytomegalovirus and Epstein-Barr virus were ruled out, and at last, the patient 
signed the informed consent for an HIV test. Hydration, broad-spectrum antibiotic therapy, 
paracetamol and methylprednisolone were administered. In order to rule out an 
endocarditis or an atypical pulmonary infection, an echocardiogram and a chest high-
resolution computerized tomography were performed. The echocardiogram fell within 
normal ranges (sinus rhythm at a frequency of 75 beats/min, normal atrial-ventricular and 
intraventricular conduction; electrical axis on the left; normal phase of ventricular 
repolarization). The high-resolution computerized tomography showed an unspecific 
inflammatory image at bilateral medium lobes, and a bronchoscope evaluation with 
bronchoalveolar lavage-derived liquid examination bore no specific results (alveolar 
macrophages and neutrophils). During imaging procedures, the HIV test was positive 
(780,000 copies/ml) whereby a highly active antiretroviral therapy (HAART; ritonavir, 
atazanavir, emtricitabine, tenofovir) was administered. Unpredictably, though all 
antipsoriatic treatments were interrupted, psoriasis improved dramatically with a complete 
resolution of the erythroderma (PASI 0) only 2 weeks after the introduction of HAART (fig. 
1). Such improvement of skin symptoms correlates with the rapid depletion of viral copies 
and the impressive increase in total lymphocytes (791 cells/ml and 2,235 cells/ml at 
baseline and at week 2, respectively) and CD3+/CD45+ T cell count (520 cells/ml and 
1,739 cells/ml at baseline and week 2, respectively). After 24 weeks, total lymphocytes 
and CD3+/CD45+ T cell count were within normal ranges and the patient showed a 
complete remission of psoriasis. HCV viral load as well as liver functionality and structure 
were strictly monitored during the period of observation. We did not find any progression of 
the HCV infection, and according to the infectious disease consultations, we did not 
administer any specific anti-HCV treatment. 
 
Review of the literature 
It is uncertain whether the prevalence of psoriasis and psoriatic arthritis in HIV-infected 
subjects may be different with respect to the general population, but the clinical behavior of 
psoriasis seems to be altered among immunosuppressed patients. In particular, clinical 
observations demonstrate that HIV-affected psoriatic patients have a severe and 
prolonged clinical course with more frequent exacerbations, and that the development of 
skin lesions or arthritis symptoms in untreated HIV patients is associated with a poor 
prognosis and a mean survival expectancy ranging from 4 to 24 months after psoriasis 
onset [3,4,5]. These observations are of interest because T lymphocytes are crucially 
involved in both diseases but, while psoriasis results from T-cell activation, HIV infection 
switching to overt AIDS determines a massive T-cell depletion. Psoriasis in HIV patients 
usually develops in severe AIDS stages (CD4+ cell count less than 100 cells/µl) [6]. In 
contrast, in immunocompetent psoriatic patients, the treatment with an anti-CD11a 
antibody, which leads to a marked T-cell reduction, was demonstrated to be significantly 
effective in improving skin lesions [7]. The occurrence of psoriasis in AIDS patients may be 
correlated with an increase in CD8+ T cells in the peripheral blood, reflecting the psoriasis 
relapses in immu-nocompetent patients due to a significant infiltration of CD8+ T cells both 
in the epidermis and dermis of lesional skin. Notably, in patients with CD4+ cell counts of 
less than 200 cells/µl, memory CD8+ T cells producing IL-17 and IFN-γ comprise over 
80% of the T cells in peripheral blood [2]. 
 In 2009, the estimated number (expressed as percent of the total population in that age 
group) of HIV-infected young adults (15-49 years), whether or not they have developed 
AIDS, was 0.3 and 0.6 in Italy and in the USA, respectively (Global Health Observatory 
Data Repository, http://apps.who.int/ghodata). Consequently, an undiagnosed HIV 
infection must be carefully ruled out when an immunosuppressant is administered. 
However, when an HIV infection is diagnosed, the treatment of psoriasis is challenging. 
Despite the number of agents that have been proposed for this subset of patients, several 
reports exhibit controversial clinical outcomes. Although topical agents prevail as therapy 
of choice in HIV-infected patients, they prove somewhat ineffective in the treatment of 
widespread plaque-type psoriasis or in severe clinical variants, including pustular psoriasis 
and erythroderma. In these forms, the Medical Board of the National Psoriasis Foundation 
recommends UVB or psoralen plus UVA (PUVA) phototherapy [8,9], though the increased 
risk for skin cancer, increase in HIV viral load and reduced resistance to infections should 
be carefully taken into consideration [2]. 
Acitretin, 75 mg/day, has been reported as effective in one report [10], and an additional 
benefit was reached when ultraviolet light was combined in a RePUVA regimen [11]. 
Accordingly, systemic ret-inoids may be considered as first-line agents, although their use 
must be limited because of their contraindication (e.g. hepatic insufficiency or infections 
and alcohol intake), particularly in HIV high-risk cohorts (e.g. drug addicts). Concerning 
other systemic agents, methotrexate can be associated with severe leukopenia and death 
in HIV-infected psoriatic patients and, thus, should be used with great caution [12,13]. Also, 
the use of cyclosporine and its benefits are controversial although cyclosporine may be 
potentially beneficial [14]. Indeed, in some reported cases, this agent was effective and safe 
in treating HIV-correlated psoriasis, whereas in other cases, as in our report, it was found 
to be ineffective and unsafe [15,16,17,18]. The use of other antipsoriatic agents in HIV 
patients, including mycophenolate mofetil or hydroxyurea, is anecdotic [19]. Since TNF-α 
stimulates HIV transcription in vitro and could be involved in the pathogenesis of fatigue, 
fever and cachexia, theoretically, TNF-α-blocking agents should be effective [20]. 
Furthermore, TNF-α is a pivotal mediator in granulomatous inflammation, generating 
concern about the use of anti-TNF-α in HIV patients, who often suffer from other 
comorbidities, including tuberculosis, hepatitis B and other opportunistic infections. In fact, 
etanercept, a soluble TNF-α receptor, has been effectively used, at a dosage of 25 or 50 
mg, in patients with HIV-associated psoriasis or psoriatic arthritis [21,22], though one of the 
treated patients withdrew due to frequent bacterial infections, not definitely related to the 
biological [20]. It is of note, in all patients, that the CD4+ cell count remains stable, and in 
one of them viral load was undetectable after 20 weeks [22]. In-fliximab, a monoclonal anti-
TNF-α antibody, was also demonstrated as effective and safe in HIV patients, rapidly 
improving both joint symptoms and skin lesions, and maintaining the therapeutic effect 
throughout a long-term follow up [23].  These observations have been bolstered by another 
report on a patient effectively treated with a low dose (3 mg/kg instead of 5 mg/kg) of 
infliximab [24]. These data are promising although further and larger trials are needed to 
validate these reports. Concerning nonantipsoriatic treatments, antiretroviral therapies 
have been demonstrated effective in treating psoriasis in single reported cases 
[25,26,27,28,29]. They include protease inhibitors (lamivudine, saquinavir, ritonavir) used as 
monotherapy or combined to nonnucleoside reverse transcriptase inhibitors (zidovudine, 
nevirapine, stavudine, tenofovir), or in addition to an entry inhibitor (enfuvirtide) [30,31]. To 
our knowledge, only one open-label clinical trial on 19 evaluable patients treated with 
zidovudine has been performed. It showed marked efficacy in treating psoriasis with an 
improvement of skin manifestations in 90% of cases [32]. The usual HAART regimen 
contemplates different combinations of nucleoside reverse transcriptase inhibitors, 
protease inhibitors, and nonnucleoside reverse transcriptase inhibitors, and it has proven 
beneficial in HIV-associated psoriasis [33].  Of note, zidovudine is rarely used in modern 
HAART regimens because of adverse effects, including dyslipidemia and lipoatrophy [2]. 
Though the resolution of psoriasis following HAART was often observed to be concomitant 
with the decrease in HIV viral load, another case conversely demonstrated a severe 
exacerbation of psoriasis during the treatment, resulting in raised CD4 and CD8 cell 
counts [34]. In our patient, HAART dramatically resolved skin lesions (PASI 48 and PASI 0 
at baseline and at week 2, respectively) and concomitantly normalized the total T-cell 
count (791 and 2,235 cells/ml at baseline and at week 2, respectively) and CD3+/CD45+ 
T-cell count (520 and 1,739 cells/ml at baseline and week 2, respectively), demonstrating 
a more rapid efficacy than previous reported therapies. No exacerbation of psoriasis has 
been observed after the immune system restoration and no side effects were observed or 
reported by the patient during the treatment. 
 
Conclusion 
We described a psoriatic patient who was refractory or contraindicated to almost all known 
agents because of a latent, undiagnosed HIV infection, which might directly trigger 
psoriasis as a costimulatory factor through either antigenic presentation or as a source of 
superantigens [8]. Generally, a latent infection could be easily excluded by laboratory tests 
but the legal need of a specific, written consent to perform an HIV test poses an obstacle, 
with the majority of patients reluctant to perform it. This resistance to testing is likely 
attributed to a wrong social and cultural heritage and to the implications of a possible 
positivity. The HIV test is not routinely performed and is not mandatory as a screening test 
for biological therapies. However, the physician should strongly recommend the HIV test to 
high-risk patient cohorts or in patients with a multidrug resistance because HAART could 






Fig. 1. a Erythrodermic flare (PASI 48) occurred before HAART. b Resolution of the erythrodermic 
flare (PASI 0) after 2 weeks of HAART. c Reduction of the HIV viral load was rapidly observed 
after the introduction of HAART. d Increased total lymphocyte count and CD3+/CD45+ T-cell count 
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